Evidence map›Paper›PMID 11283260›Full record

ArticleMolecular and cellular biology2001

Reduction of target gene expression by a modified U1 snRNA.

S A Beckley, P Liu, M L Stover, S I Gunderson, A C Lichtler, D W Rowe

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The reciprocal regulation between splicing and 3'-end processing.Wiley interdisciplinary reviews. RNA · 2016
    Review
  5. Article
  6. Quality control of assembly-defective U1 snRNAs by decapping and 5'-to-3' exonucleolytic digestion.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Gene silencing by synthetic U1 adaptors.Nature biotechnology · 2009
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

S A BeckleyDepartment of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, Connecticut 06030, USA.
P Liu
M L Stover
S I Gunderson
A C Lichtler
D W Rowe
UConn Health · USRutgers, The State University of New Jersey · US

Funding

Regulation of Polyadenylation: the U1A/U1snRNP ParadigmR01GM057286 · NIGMS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI GUNDERSON, SAMUEL I · 1999 to 2007
$2.9M
TYPE I COLLAGEN MRNA IN OSTEOGENESIS IMPERFECTAR01AR030426 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI ROWE, DAVID W · 1986 to 1999
–
NIAMS NIH HHS AR 30426NIGMS NIH HHS GM57286NIGMS NIH HHS R01 GM057286
6 · The paper itself

Abstract

Although the primary function of U1 snRNA is to define the 5' donor site of an intron, it can also block the accumulation of a specific RNA transcript when it binds to a donor sequence within its terminal exon. This work was initiated to investigate if this property of U1 snRNA could be exploited as an effective method for inactivating any target gene. The initial 10-bp segment of U1 snRNA, which is complementary to the 5' donor sequence, was modified to recognize various target mRNAs (chloramphenicol acetyltransferase [CAT], beta-galactosidase, or green fluorescent protein [GFP]). Transient cotransfection of reporter genes and appropriate U1 antitarget vectors resulted in >90% reduction of transgene expression. Numerous sites within the CAT transcript were suitable for targeting. The inhibitory effect of the U1 antitarget vector is directly related to the hybrid formed between the U1 vector and target transcripts and is dependent on an intact 70,000-molecular-weight binding domain within the U1 gene. The effect is long lasting when the target (CAT or GFP) and U1 antitarget construct are inserted into fibroblasts by stable transfection. Clonal cell lines derived from stable transfection with a pOB4GFP target construct and subsequently stably transfected with the U1 anti-GFP construct were selected. The degree to which GFP fluorescence was inhibited by U1 anti-GFP in the various clonal cell lines was assessed by fluorescence-activated cell sorter analysis. RNA analysis demonstrated reduction of the GFP mRNA in the nuclear and cytoplasmic compartment and proper 3' cleavage of the GFP residual transcript. An RNase protection strategy demonstrated that the transfected U1 antitarget RNA level varied between 1 to 8% of the endogenous U1 snRNA level. U1 antitarget vectors were demonstrated to have potential as effective inhibitors of gene expression in intact cells.

Indexed as

Gene Expression3T3 CellsAnimalsBase Sequencebeta-GalactosidaseChloramphenicol O-AcetyltransferaseDNAGenes, ReporterGene TargetingGreen Fluorescent ProteinsLuminescent ProteinsMiceRNA, Small NuclearTransfectionbeta-GalactosidaseChloramphenicol O-AcetyltransferaseDNAGreen Fluorescent ProteinsLuminescent ProteinsRNA, Small NuclearU1 small nuclear RNANon-programmatic

Identifiers

PMID11283260
PMCPMC86911
OpenAlexW2122162055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.